Table 1 Characteristics of the included studies
Author (et al.) | Year | OC (no.) | Controls (no.) | Histological subtype | Stage | Initial target gene(s) selection and clinical purpose of biomarker |
|---|---|---|---|---|---|---|
de Caceres [18] | 2004 | 50 (T) | 10b/20h (T) | Papillary serous Endometrioid Mucinous Clear cell Transitional cell | I/III/IV | Previous research Detection |
Su [19] | 2009 | 26 (T) | 20b (T) | Serous Endometrial Mucinous | N/A | Previous research Detection/prognostic |
Melnikov [20] | 2009 | 33 (T) | 33h (T) | Papillary serous | III/IV | Global screening Detection |
BonDurant [21] | 2011 | 21 (T) | 7h (T) | Serous | I–IV | Global screening Detection |
Campan [22] | 2011 | 16 (T) | 8h (T) | Serous Endometrioid Mucinous | III/IV | Global screening Detection |
Häfner [23] | 2011 | 32 (T) | 30b/20h (T) | Serous Endometrioid Papillary Clear cell Neuroendocrine | II–IV | Previous research Detection |
Liggett [24] | 2011 | 30 (T) | 30b/30h (T) | Serous | III/IV | Semi-global screening Detection |
Dong [25] | 2012 | 36 (T) | 25h (T) | Serous Endometrioid Mucinous | I–IV | Previous research Detection |
Wang [26] | 2013 | 60 (T) | 30b/30h (T) | Serous Endometrioid Mucinous Clear cell | I–III | Previous research Detection |
Zhang [27] | 2013 | 87 (T) 39 (V) | 53b/62h (T) 29b (V) | Serous Endometrioid Mucinous Clear cell Mixed | I–IV (T) I–III (V) | Previous research Detection |
Wu [28] | 2014 | 47 (T) | 14b/10h (T) | Serous Endometrioid Mucinous | I–IV | Previous research Detection |
Zhou [29] | 2014 | 45 (T) | 60h (T) | Serous Endometrioid Mucinous Clear cell Undifferentiated | I–IV | Previous research Detection |
Wang [30] | 2015 | 71 (T) | 43b/80h (T) | Serous Endometrioid Mucinous Clear cell | I–IV | Previous research Detection |
Giannopoulou [31] | 2017 | 59 (T) | 51h (T) | High grade serous | N/A | Previous research Prognostic |
Swellam [32] | 2017 | 90 (T) | 50b/30h (T) | Serous Endometroid Mucinous | I–IV | Previous research Detection |
Wang [33] | 2017 | 71 (T) | 43b/80h (T) | N/A | I–IV | Previous research Detection |
Widschwendter [34] | 2017 | 29 (T) 48 (V) | 119b/21h (T) 154b/41h (V) | High grade serous Endometrioid Clear cell Mucinous Carcinosarcoma | I–IV | Global screening Detection |
Giannopoulou [35] | 2018 | 50 (T) | 51h (T) | Serous | I–IV | Previous research Prognostic |
Dvorská [36] | 2019 | 33 (T) | 5b/3bc−oc/9h (T) | Serous Serous papillary Endometrioid Mucinous Clear cell | N/A | Previous research Detection/prediction of risk |
Kumar [37] | 2019 | 53 (T) | 12b/7lmp/15h (T) | Serous Endometroid Mucinous Clear cell | I–IV | Previous research Detection/prognostic |
Liu [11] | 2020 | 27 (T) 12 (V) | 1521h (T) 610h (V) | Fallopian tube Primary peritoneal | N/A | Global screening Detection |
Miller [38] | 2020 | 26 (T) 8 (V) | 41h (T) 12h (V) | Serous Non-serous | N/A | Previous research Detection |
Singh [39] | 2020 | 45 (T) | 25h (T) | Serous Mucinous | I–IV | Previous research Detection |
Faaborg [40] | 2021 | 26 (V) 79 (A) | 64h (T) | Low-grade serous High-grade serous Endometrioid Mucinous | I–IV | Previous research Detection |
Miller [41] | 2021 | 38 (T) | 20h (T) | N/A | III/IV | Previous research Detection |
Singh [42] | 2021 | 45 (T) | 25h (T) | Serous Mucinous | I–IV | Previous research Detection |
Tserpeli [43] | 2021 | 84 (T) 49 (T) | 27h (T) | High grade serous | III/IV | Previous research Prognostic |
Marinelli [44] | 2022 | 91 (T) | 91h (T) | Low grade serous High grade serous Endometrioid Mucinous Clear cell | I–IV | Global screening Detection |
Tomeva [45] | 2022 | 19 (T) | 8h (T) | N/A | II/III | Previous research Detection |